Delta G Avaris
Because Every Life Counts:Saving Lives Through Personalized Phage Therapy
Saving Lives and Improving Quality of Life with Personalized Phage Therapy
About the Company
Our Goal
We combat antimicrobial resistance (AMR) with personalized phage therapy — from analysis to application.
About the Company
Our Goal
Our goal is to combat antimicrobial resistance (AMR) using a holistic, personalized phage-therapy approach that spans the full pipeline from analysis to application.
Scientific Publications
Scientific papers on phage research in peer-reviewed journals.
Research & Development
Phage therapy is an answer to the ESKAPE pathogens that threaten millions of lives worldwide.
Our Team
An interdisciplinary team of scientists, physicians, and experts.
Our Solution
Reimagining Infection Solutions Through Phage Therapy
Phage therapy is an answer to the ESKAPE pathogens that threaten millions of lives worldwide. We are making this revolutionary approach ready for use in everyday medical practice through the combination of precise, industrial, GMP-certified active ingredient production and an established supply chain for the magistral treatment of ESKAPE pathogens.
GMP-certified phage therapy for everyday medical practice — against ESKAPE pathogens.
News
Press & News
Delta G Avaris acquires GMP production site of Richter Biologics in Hannover for phage manufacturing
Participation in ESCMID Global 2026: Advances in Phage Therapy from Hanover
Delta G Avaris receives approximately €900,000 in research funding for the further development of phage therapy
Information for Healthcare Professionals
Further professional information and scientific data are exclusively available to healthcare professionals in the protected area.
Scientific data — exclusively for healthcare professionals.